Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 50, 2013, Pages 20224-20229

  Liu, Jun ^a   Pan, Shifeng ^a   Hsieh, Mindy H ^a   Ng, Nicholas ^a   Sun, Fangxian ^a   Wang, Tao ^b   Kasibhatla, Shailaja ^a   Schuller, Alwin G ^b   Li, Allen G ^a   Cheng, Dai ^a   Li, Jie ^a   Tompkins, Celin ^a   Pferdekamper, AnneMarie ^a   Steffy, Auzon ^a   Cheng, Jane ^b   Kowal, Colleen ^b   Phung, Van ^a   Guo, Guirong ^a   Wang, Yan ^a   Graham, Martin P ^c   Flynn, Shannon ^c   Brenner, J Chad ^c   Li, Chun ^a   Villarroel, M Cristina ^b   Schultz, Peter G ^a,d   Wu, Xu ^a,e   McNamara, Peter ^a   Sellers, William R ^b   Petruzzelli, Lilli ^b   Boral, Anthony L ^b   Seidel, H Martin ^a   McLaughlin, Margaret E ^b   Che, Jianwei ^a   Carey, Thomas E ^c   Vanasse, Gary ^b   Harris, Jennifer L ^a   more..

^a GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

catenin; HNSCC; Wnt inhibition

Indexed keywords

ACYLTRANSFERASE; LGK974; PORCUPINE ACYLTRANSFERASE; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; DRUG BIOAVAILABILITY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; HEAD AND NECK CANCER; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; LOSS OF FUNCTION MUTATION; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PALMITOYLATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN SECRETION; RAT; TUMOR REGRESSION; TUMOR XENOGRAFT; WNT SIGNALING PATHWAY;

EID: 84890281677     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1314239110     Document Type: Article

References (47)

1. Polakis P (2012) Wnt signaling in cancer. Cold Spring Harb Perspect Biol 4(5):pii:a008052.
2. Nusse R, Varmus H (2012) Three decades of Wnts: A personal perspective on how a scientific field developed. EMBO J 31(12):2670-2684.
3. Clevers H, Nusse R (2012) Wnt/β-catenin signaling and disease. Cell 149(6):1192-1205.
4. Seshagiri S, et al. (2012) Recurrent R-spondin fusions in colon cancer. Nature 488(7413):660-664.
5. Hao HX, et al. (2012) ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nature 485(7397):195-200.
6. Koo BK, et al. (2012) Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature 488(7413):665-669.
7. Theodorou V, et al. (2007) MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer. Nat Genet 39(6):759-769.
8. Howe LR, Brown AM (2004) Wnt signaling and breast cancer. Cancer Biol Ther 3(1):36-41.
9. Geyer FC, et al. (2011) β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol 24(2):209-231.
10. Khramtsov AI, et al. (2010) Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol 176(6):2911-2920.
11. Gurney A, et al. (2012) Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci USA 109(29):11717-11722.
12. Malanchi I, et al. (2008) Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature 452(7187):650-653.
13. Heidel FH, et al. (2012) Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell 10(4):412-424.
14. Wang Y, et al. (2010) The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 327(5973):1650-1653.
15. Herr P, Hausmann G, Basler K (2012) WNT secretion and signalling in human disease. Trends Mol Med 18(8):483-493.
16. Takada R, et al. (2006) Monounsaturated fatty acid modification of Wnt protein: Its role in Wnt secretion. Dev Cell 11(6):791-801.
17. Biechele S, Cox BJ, Rossant J (2011) Porcupine homolog is required for canonical Wnt signaling and gastrulation in mouse embryos. Dev Biol 355(2):275-285.
18. Barrott JJ, Cash GM, Smith AP, Barrow JR, Murtaugh LC (2011) Deletion of mouse Porcn blocks Wnt ligand secretion and reveals an ectodermal etiology of human focal dermal hypoplasia/Goltz syndrome. Proc Natl Acad Sci USA 108(31):12752-12757.
19. Huang SM, et al. (2009) Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461(7264):614-620.
20. Nusse R (2003) Wnts and Hedgehogs: Lipid-modified proteins and similarities in signaling mechanisms at the cell surface. Development 130(22):5297-5305.
21. Cheng D, Zhang G, Han D, Gao W, Pan S (2010) N-(hetero) aryl, 2-(hetero) aryl-substituted acetamides for use as Wnt signaling modulators. Patent Cooperation Treaty and US patent publication US 101849 (2010).
22. Proffitt KD, et al. (2013) Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer. Cancer Res 73(2):502-507.
23. Kuhnert F, et al. (2004) Essential requirement for Wnt signaling in proliferation of adult small intestine and colon revealed by adenoviral expression of Dickkopf-1. Proc Natl Acad Sci USA 101(1):266-271.
24. van Es JH, et al. (2012) A critical role for the Wnt effector Tcf4 in adult intestinal homeostatic self-renewal. Mol Cell Biol 32(10):1918-1927.
25. Barker N, et al. (2010) Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell 6(1):25-36.
26. Huelsken J, Vogel R, Erdmann B, Cotsarelis G, Birchmeier W (2001) beta-Catenin controls hair follicle morphogenesis and stem cell differentiation in the skin. Cell 105(4):533-545.
27. Agrawal N, et al. (2011) Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333(6046):1154-1157.
28. Stransky N, et al. (2011) The mutational landscape of head and neck squamous cell carcinoma. Science 333(6046):1157-1160.
29. Kopan R (2012) Notch signaling. Cold Spring Harb Perspect Biol 4(10):pii:a011213.
30. Proweller A, et al. (2006) Impaired notch signaling promotes de novo squamous cell carcinoma formation. Cancer Res 66(15):7438-7444.
31. Nicolas M, et al. (2003) Notch1 functions as a tumor suppressor in mouse skin. Nat Genet 33(3):416-421.
32. Devgan V, Mammucari C, Millar SE, Brisken C, Dotto GP (2005) p21WAF1/Cip1 is a negative transcriptional regulator of Wnt4 expression downstream of Notch1 activation. Genes Dev 19(12):1485-1495.
33. Takeyama K, et al. (2003) The BAL-binding protein BBAP and related Deltex family members exhibit ubiquitin-protein isopeptide ligase activity. J Biol Chem 278(24):21930-21937.
34. Guruharsha KG, Kankel MW, Artavanis-Tsakonas S (2012) The Notch signalling system: Recent insights into the complexity of a conserved pathway. Nat Rev Genet 13(9):654-666.
35. Gong Y, et al. (2010) Wnt isoform-specific interactions with coreceptor specify inhibition or potentiation of signaling by LRP6 antibodies. PLoS One 5(9):e12682.
36. Ettenberg SA, et al. (2010) Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies. Proc Natl Acad Sci USA 107(35):15473-15478.
37. Chen B, et al. (2009) Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 5(2):100-107.
38. Dodge ME, et al. (2012) Diverse chemical scaffolds support direct inhibition of the membrane-bound O-acyltransferase porcupine. J Biol Chem 287(27):23246-23254.
39. Lau T, et al. (2013) A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Cancer Res 73(10):3132-3144.
40. Lobry C, Oh P, Aifantis I (2011) Oncogenic and tumor suppressor functions of Notch in cancer: It' s NOTCH what you think. J Exp Med 208(10):1931-1935.
41. Demehri S, Turkoz A, Kopan R (2009) Epidermal Notch1 loss promotes skin tumorigenesis by impacting the stromal microenvironment. Cancer Cell 16(1):55-66.
42. Agrawal N, et al. (2012) Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov 2(10):899-905.
43. Wang NJ, et al. (2011) Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci USA 108(43):17761-17766.
44. Unger S, et al. (2008) Mutations in the cyclin family member FAM58A cause an X-linked dominant disorder characterized by syndactyly, telecanthus and anogenital and renal malformations. Nat Genet 40(3):287-289.
45. Morris LG, et al. (2013) Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nat Genet 45(3):253-261.
46. Pickering CR, et al. (2013) Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov 3(7):770-781.
47. Beronja S, et al. (2013) RNAi screens in mice identify physiological regulators of oncogenic growth. Nature 501(7466):185-190.